LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

‘NEUROSTEM-AD’ the treatment for Alzheimer’s disease requested for phase 1.2a clinical trials

2013/06/28
STEM CELL THERAPEUTIC

MEDIPOST has made a request to conduct phase 1.2a clinical trial using ‘NEUROSTEM-AD’ a treatment agent for Alzheimer’s disease using stem cells on June 28 to the FDA.

This study is receiving attention from various academies and ministries of the health of various countries in the era of difficulties with the development of treatment for Alzheimer’s disease, as it is the first in the world to use stem cells.

MEDIPOST successfully conducted the phase 1 clinical trial using ‘NEUROSTEM-AD’ between November 2010 and December 2011, and has since been conducting additional preclinical studies for the next year to study the routes of administration and methods.

Unlike the administration of NEUROSTEM-AD through surgery into the brain once, during the first clinical trial, in the 1.2a clinical trial, they have changed the method to the administration to cerebrospinal fluid three times to improve the patient convenience.

Once the approval for clinical trial for NEUROSTEM-AD is given, MEDIPOST will be investigating the efficacy and safety of this agent together with the Samsung Seoul Medical Center for the next 2 years.

VIEW LIST

Related News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14
MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 P…
2024/06/24

Latest News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14
MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 P…
2024/06/24

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Recruits Local Experts to U.S.…2024.12.06
MEDIPOST Completes Administration for Ph…2024.11.22
MEDIPOST Affiliate OmniaBio Hosts Openin…2024.10.21
MEDIPOST Discusses CARTISTEM® Partnershi…2024.10.14
MEDIPOST’s CARTISTEM® Reaches Milestone…2024.06.24

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST